ArticleJournal of lipid research2020
Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation.
Article in Journal of lipid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Insulin resistance in obese children and adolescents: from mechanisms to screening and exercise intervention.Frontiers in pediatrics · 2026Review
- Effect of Fatty Acids on Glucose Metabolism and Type 2 Diabetes.Nutrition reviews · 2025Review
- Interplay of fatty acids, insulin and exercise in vascular health.Lipids in health and disease · 2025Review
- Dietary medium-chain fatty acids reduce hepatic fat accumulation via activation of a CREBH-FGF21 axis.Molecular metabolism · 2024Article
- Nomogram model for the risk of insulin resistance in obese children and adolescents based on anthropomorphology and lipid derived indicators.BMC public health · 2023Article
- The anti-diabetic effects of metformin are mediated by regulating long non-coding RNA.Frontiers in pharmacology · 2023Review
- Mechanisms of Myocardial Damage Due to Hyperlipidemia: A Review of Recent Studies.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Metabolic Determinants in Cardiomyocyte Function and Heart Regenerative Strategies.Metabolites · 2022Review
- DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.Journal of the American Society of Nephrology : JASN · 2022Article
- Mitochondrial oxidative function in NAFLD: Friend or foe?Molecular metabolism · 2021Review
- Review
- Enhancing Fatty Acids OxidationFrontiers in pharmacology · 2021Article
- New Insights Into Mitochondrial Dysfunction at Disease Susceptibility Loci in the Development of Type 2 Diabetes.Frontiers in endocrinology · 2021Article
- Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise.Nature reviews. Endocrinology · 2020Review
- Article
- The Discovery of Highly Potent THP Derivatives as OCTN2 Inhibitors: From Structure-Based Virtual Screening to In Vivo Biological Activity.International journal of molecular sciences · 2020Article
- The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD).Nutrients · 2020Review
- Recent advances in understanding glucose transport and glucose disposal.F1000Research · 2020Review
- Oral GLP1 Analog: Where Does the Tide Go?Clinical medicine insights. Endocrinology and diabetes · 2020Review
- Changes in Myocardial Metabolism Preceding Sudden Cardiac Death.Frontiers in physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive circulating FAs have been proposed to promote insulin resistance (IR) of glucose metabolism by increasing the oxidation of FAs over glucose. Therefore, inhibition of FA oxidation (FAOX) has been suggested to ameliorate IR. However, prolonged inhibition of FAOX would presumably cause lipid accumulation and thereby promote lipotoxicity. To understand the glycemic consequences of acute and prolonged FAOX inhibition, we treated mice with the carnitine palmitoyltransferase 1 (CPT-1) inhibitor, etomoxir (eto), in combination with short-term 45% high fat diet feeding to increase FA availability. Eto acutely increased glucose oxidation and peripheral glucose disposal, and lowered circulating glucose, but this was associated with increased circulating FAs and triacylglycerol accumulation in the liver and heart within hours. Several days of FAOX inhibition by daily eto administration induced hepatic steatosis and glucose intolerance, specific to CPT-1 inhibition by eto. Lower whole-body insulin sensitivity was accompanied by reduction in brown adipose tissue (BAT) uncoupling protein 1 (UCP1) protein content, diminished BAT glucose clearance, and increased hepatic glucose production. Collectively, these data suggest that pharmacological inhibition of FAOX is not a viable strategy to treat IR, and that sufficient rates of FAOX are required for maintaining liver and BAT metabolic function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.